Medscape is available in 5 Language Editions – Choose your Edition here.



  • Author: G Willy Davila, MD; Chief Editor: Michel E Rivlin, MD  more...
Updated: Apr 25, 2016

Practice Essentials

Endometriosis is defined as the presence of normal endometrial mucosa (glands and stroma) abnormally implanted in locations other than the uterine cavity (see the image below). Approximately 30-40% of women with endometriosis will be subfertile.

Endometriosis. Red lesions on various organs. Endometriosis. Red lesions on various organs.

Signs and symptoms

About one third of women with endometriosis remain asymptomatic.[1] When they do occur, symptoms, such as the following, typically reflect the area of involvement:

  • Dysmenorrhea
  • Heavy or irregular bleeding
  • Pelvic pain
  • Lower abdominal or back pain [2]
  • Dyspareunia
  • Dyschezia (pain on defecation) - Often with cycles of diarrhea and constipation
  • Bloating, nausea, and vomiting
  • Inguinal pain
  • Pain on micturition and/or urinary frequency
  • Pain during exercise

Patients with endometriosis do not frequently have any physical examination findings beyond tenderness related to the site of involvement.[3, 4, 5] The most common finding is nonspecific pelvic tenderness.

See Clinical Presentation for more detail.



Laparoscopy is considered the primary diagnostic modality for endometriosis. This is an invasive procedure with an overall sensitivity of 97% but with a specificity of only 77%.

The following sites are, in descending order, the most common sites of involvement found during laparoscopy:

  • Ovaries
  • Posterior cul-de-sac
  • Broad ligament
  • Uterosacral ligament
  • Rectosigmoid colon
  • Bladder
  • Distal ureter


Histologic demonstration of a combination of endometrial glands and stroma in biopsy specimens obtained from outside the uterine cavity is required to make the diagnosis of endometriosis.

Laboratory studies

  • Complete blood count (CBC) with differential - May help to differentiate pelvic infection from endometriosis, as well as to assess the degree of blood loss
  • Urinalysis and urine culture - If urinary tract infection (UTI) is in the differential diagnosis
  • Cervical Gram stain and cultures - Because sexually transmitted diseases (STDs) can also cause pelvic pain and infertility

Imaging studies

  • Ultrasonography - Endometriosis can be assessed by either transvaginal ultrasonography or endorectal ultrasonography
  • Magnetic resonance imaging (MRI)

See Workup for more detail.


The dependence of endometriosis on the cyclic production of menstrual cycle hormones provides the basis for medical therapy. Thus, the following drugs form the mainstay of pharmacologic care:

  • Combination oral contraceptive pills (COCPs)
  • Danazol
  • Progestational agents
  • Gonadotropin-releasing hormone (GnRH) analogues

Surgical care for endometriosis can be broadly classified as follows:

  • Conservative - When reproductive potential is retained
  • Semiconservative - When reproductive ability is eliminated but ovarian function is retained
  • Radical - When the uterus and ovaries are removed

Conservative surgery

Conservative procedures used in the treatment of endometriosis include the following:

  • Drainage and laparoscopic cystectomy - Both procedures can be used in the treatment of ovarian endometriosis
  • Ablation
  • Presacral neurectomy
  • Laparoscopic uterine nerve ablation (LUNA)

Semiconservative surgery

Semiconservative surgery is indicated mainly for women who have completed childbearing, are too young to undergo surgical menopause, and are debilitated by the symptoms. Such surgery involves hysterectomy and cytoreduction of pelvic endometriosis.

Ovarian endometriosis can be removed surgically, because one tenth of functioning ovarian tissue is all that is needed for hormone production. (Patients who undergo hysterectomy with ovarian conservation have a 6-fold higher rate of recurrence compared to women who undergo oophorectomy.[6] )

Radical surgery

Radical surgery involves total hysterectomy with bilateral oophorectomy (TAH-BSO) and cytoreduction of visible endometriosis. Adhesiolysis is performed to restore mobility and normal intrapelvic organ relationships.

See Treatment and Medication for more detail.



Ectopic endometrial tissues are most commonly located in the dependent portions of the female pelvis (eg, posterior and anterior cul-de-sac, uterosacral ligaments, tubes, ovaries), but any organ system is potentially at risk (see the following images).

Typical appearance of minimal endometriosis on the Typical appearance of minimal endometriosis on the uterosacral ligaments. Note that some are pigmented (contain hemosiderin), whereas others are not.
Peritoneal erosions and adhesions in the posterior Peritoneal erosions and adhesions in the posterior cul-de-sac. These are typical of more severe endometriosis.

These ectopic foci respond to cyclic hormonal fluctuations in much the same way as intrauterine endometrium, with proliferation, secretory activity, and cyclic sloughing of menstrual material. The products of this metabolic activity, including the concentrated and cyclic release of cytokines and prostaglandins, lead to an altered inflammatory response characterized by neovascularization and fibrosis formation. Some investigators have been able to demonstrate abnormal T- and B-cell function, abnormal complement deposition, and altered interleukin (IL)-6 production in women with this disease.

The associated pain, adhesion formation (see the image below), and anatomic distortion are responsible for the clinical consequences of this disease.

Adhesions due to endometriosis. Adhesions due to endometriosis.


The exact cause and pathogenesis of endometriosis is unclear. Several theories exist that attempt to explain this disease, although none have been entirely proven.[1] Leading theories include metaplastic conversion of coelomic epithelium and hematogenous or lymphatic dispersion of endometrial cells. It is likely a combination of various factors that cause and determine the severity of this disease.

Previous theories suggest that endometriosis results from the transport of viable endometrial cells through retrograde menstruation. Cells flow backward through the fallopian tubes and deposit on the pelvic organs, where they seed and grow. A population of cells resides in the endometrium, which retain stem cell properties. It may be these properties that allow these cells to survive in ectopic locations.

Risk factors for endometriosis include the following:

  • Family history of endometriosis
  • Early age of menarche
  • Short menstrual cycles (< 27 d)
  • Long duration of menstrual flow (>7 d)
  • Heavy bleeding during menses
  • Inverse relationship to parity
  • Delayed childbearing
  • Defects in the uterus or fallopian tubes
  • Hypoxia and iron deficiency may contribute to the early onset of endometriosis

Retrograde menstruation

Early in the 20th century (1927), Samson proposed his theory of retrograde menstruation through the fallopian tubes into the peritoneal cavity as a cause of endometriosis. Subsequent studies have shown that retrograde menstruation is a quite common physiologic event and cannot adequately explain the extrauterine implantation of endometrial tissue. Diagnostic laparoscopy during the perimenstrual period has shown that as many as 90% of women with patent fallopian tubes have bloody peritoneal fluid. Nonetheless, conditions that increase the rate of retrograde menstruation, such as congenital outflow tract obstructions, do increase the risk of endometriosis. Various animal experiments and clinical observations support this theory.[7, 8, 9, 10]

Because most women do not have endometriosis, perhaps immunologic or hormonal dysfunction leaves some women predisposed.

Immunologic dysfunction

Relatively recent research has suggested involvement of the immune system in the pathogenesis of endometriosis. An altered immune response to the displaced endometrial tissue has been shown to play an important role as well. Women with this disorder appear to exhibit increased humoral immune responsiveness and macrophage activation while showing diminished cell-mediated immunity with decreased T-cell and natural killer cell responsiveness. Humoral antibodies to endometrial tissue have also been found in sera of women with endometriosis.[11]

Intriguing nonhuman primate studies have demonstrated a strong association between dioxane exposure and the development of endometriosis, implying further that dysfunction of the immune system may contribute to this disease. However, epidemiologic investigations have not been able to confirm this association in humans.

Studies in recent years have focused on assessing the differences between eutopic endometrium and endometriosis. In endometriosis, an aberrantly expressed factor SF-1 activates the expression of the enzyme aromatase, which converts C19 steroids to estrogens. Consequently, estrogen increases the synthesis of prostaglandin E2, which exerts a positive feedback effect, resulting in increased aromatase activity. Additionally, endometriotic tissue is deficient in the enzyme 17-beta hydroxy steroid dehydrogenase type 2, which converts E2 in eutopic endometrium to the less potent E1 under the direction of progestins.

One study found a higher number of endometriomas, more bilateral disease, and a higher incidence of significant pain in women with aromatase positive disease.[12] However, other studies have shown increased cyclooxygenase-2 (COX-2) expression in the stromal cells[13] and aberrant aromatase expression[14] in eutopic endometrium of women with endometriosis.

Although successful treatment has been described with the aromatase inhibitor anastrozole in women with severe postmenopausal endometriosis,[15] more recent studies have also shown it to be effective in cases of severe endometriosis in premenopausal women.[16, 17] Additional data are needed before recommending this as primary treatment.


Metaplasia, or the changing from one normal type of tissue to another normal type of tissue, is another theory. The endometrium and the peritoneum are derivatives of the same coelomic wall epithelium. Transformation of coelomic epithelium into endometrial-type glands in response to as yet unknown stimuli could explain endometriosis in unusual sites.[18] Coelomic metaplasia is also believed to explain the occurrence of endometriosis in women who have undergone total hysterectomy and are not taking estrogen replacement.[19] Peritoneal mesothelium has been postulated to retain its embryologic ability to transform into reproductive tissue. Such transformation may occur spontaneously, or it may be facilitated by exposure to chronic irritation by retrograde menstrual fluid.

Endometriosis may also occur in men on high-dose estrogen therapy.[20]

Remnant Mullerian cells

Another theory states that remnant Mullerian cells may remain in the pelvic tissues during development of the Mullerian system. Under situations of estrogen stimulation, they may be induced to differentiate into functioning endometrial glands and stroma.


Some women may have a genetic predisposition to endometriosis. Studies have shown that first-degree relatives of women with this disease are more likely to develop it as well. The search for an endometriosis gene is currently under way.

Anatomic spread, dissemination and deposition

Transtubal dissemination is the most common route, although other routes, such as lymphatic and vascular channels, have been observed. This may explain how endometrial tissue can be found at distant, noncontiguous locations in the body.

Iatrogenic deposition of endometrial tissue has been found in some cases following gynecologic procedures and cesarean sections.

The ovary is the most common site for endometriosis. Spread to the ovary is believed to be lymphatic,[21] although superficial implants may be due to retrograde menstrual flow, because the ovaries are in a dependent part of the pelvis. Lesions can vary in size from spots to large endometriomas. The classic lesion is a chocolate cyst of the ovary that contains old blood that has undergone hemolysis (see the first image below). Once intracystic pressure rises, the cyst perforates, spilling its contents within the peritoneal cavity. This can cause the severe abdominal pain typically associated with endometriosis exacerbations. The inflammatory response causes adhesions that further increase the morbidity of the disease (see the second image below).

Endometriosis. Chocolate cyst of the ovary. Endometriosis. Chocolate cyst of the ovary.
Adhesions due to endometriosis. Adhesions due to endometriosis.

Uterine serosa can be affected. Vesicular lesions may provoke an inflammatory response and scarring that cause the bladder to adhere anteriorly. Posteriorly, the disease may cause obliteration of the cul-de-sac and form dense adhesions between the posterior vaginal wall or cervix and the anterior rectum. Severe dyspareunia, dyschezia, and alteration of bowel habits are the clinical sequelae of this common spread.

Deep peritoneal disease is caused by infiltration of the uterosacral ligaments and rectovaginal septum by endometriotic nodules. Tethering of the uterus can lead to fixed retroversion. Dyspareunia is an important feature.

Through contiguous spreading, endometriosis may invade the rectovaginal septum and the anterior rectal wall. It may also involve the upper rectum and sigmoid colon, infiltrating the muscularis. Cyclical rectal bleeding (hematochezia) is pathognomonic of endometriosis. However, transmural bowel involvement by endometriosis remains a rarity. The ileum, appendix, and cecum may also be involved, leading to intestinal obstruction. Cicatrization as a consequence of endometriosis may lead to symptoms of obstruction even in postmenopausal women.

Although uncommon, interference in the genitourinary tract by endometriosis can affect the bladder, ureters, and kidneys by invasion, compression, or scarring. Medical therapy has less than satisfactory results, and surgical intervention is often required.

Uncommon sites include incisional scars, the umbilicus, and the thoracic cavity. Catamenial or cyclic pneumothorax can cause hemoptysis. Remember that ectopic endometrial tissue theoretically can undergo malignant transformation; histologic evaluation may be necessary. Significant predictive factors for the presence of malignant transformation of endometriosis appear to include age older than 49 years and cysts that are multilocular and have solid components.[22] Although elevated, levels of serum cancer antigen 125 (CA-125) do not appear to be a significant predictor of malignant transformation of endometriosis.

Postmenopausal endometriosis may be encountered in women who are on estrogen replacement therapy (ERT). Occasionally, if ERT is administered after total abdominal hysterectomy, endometriosis can be stimulated in an ovarian remnant. Extrapelvic endometriosis is believed to be hormone-resistant when it occurs after surgical castration. Transplantation of endometrial implants during the original surgery is believed to explain this occurrence. Another possible explanation is coelomic metaplasia.



Endometriosis is defined as the presence of normal endometrial mucosa (glands and stroma) abnormally implanted in locations other than the uterine cavity. This tissue, possessing the same steroid receptors as normal endometrium, is capable of responding to the normal cyclic hormonal milieu. Microscopic internal bleeding, with the subsequent inflammatory response, neovascularization, and fibrosis formation, is responsible for the clinical consequences of this disease.[23]

This condition is a common, poorly understood, and extremely debilitating benign gynecologic condition. The psychologic impact of the severe pain experienced by the patient is compounded by the negative impact of the disease on fertility.[2]

In the typical patient, the ectopic implants are located in the pelvis (ovaries, fallopian tubes, vagina, cervix, or uterosacral ligaments or in the rectovaginal septum) and manifest as severe dysmenorrhea, chronic pelvic pain, or infertility. More unusual implantation sites (laparotomy scars, pleura, lung, diaphragm, kidney, spleen, gallbladder, nasal mucosa, spinal canal, stomach, breast[24, 25] ) can be responsible for bizarre symptoms such as cyclic hemoptysis and catamenial seizures.

The etiology and pathophysiology of endometriosis is not well understood because of the lack of a suitable animal model on which to study the anatomic correlates and natural history of disease.[26] No cure exists for the disease, although the hormonal responsiveness of the implants can be exploited and provides the rationale for current methods of medical therapy. Treatment is directed toward medical suppression, surgical excision, and symptom alleviation.

Adenomyosis is the invasion of the myometrium by endometrial tissue.

The following are some images of active endometriosis and old scarring.

Active endometriosis with red and powder-burn lesi Active endometriosis with red and powder-burn lesions and adhesions from old scarring.
Scarring due to old disease and active endometrios Scarring due to old disease and active endometriosis.

See also Emergent Treatment of Endometriosis and Endometrial Ablation.



Endometriosis occurs in 7-10% of US women in the general population,[27] and approximately 4 per 1000 women are hospitalized with this condition each year. The exact incidence in the general population is unknown, because the definitive diagnosis requires biopsy or visualization of the endometriotic implants at laparoscopy or laparotomy. Most prevalence studies are based on a surgical population in which the likelihood of disease is greater, with the best estimates of incidence in the general female coming from women with proven fertility undergoing tubal sterilization procedures

Endometriosis is an estrogen-dependent disease and, thus, usually affects reproductive-aged women. This condition has a prevalence rate of 20-50% in infertile women,[28, 29, 30] but it can be as high as 80% in women with chronic pelvic pain.[31] In a large series involving adolescent females with chronic pelvic pain, 45% were found to have endometriosis at laparoscopy. Of note, only 25% had a normal pelvis. In that series, the rate of endometriosis was found to increase with age from 12% in females aged 11-13 years to 45% in females aged 20-21 years.[32] In an earlier study, evidence of endometriosis was found during laparoscopy in 20-50% of asymptomatic women.[33] A familial association exists, with a 10-fold increased incidence in women with an affected first-degree relative.[34] Monozygotic twins are markedly concordant for endometriosis.[35]

Race-, sex-, and age-related differences in incidence

Most research and case studies have been performed in white populations; however, no difference appears to exist among ethnic or social groups.[36] Although endometriosis is obviously a disease largely confined to the female population, interestingly, scattered case reports exist of lesions that are histologically indistinguishable from endometriosis found in men exposed to high-dose exogenous estrogens.

Endometriosis is largely confined to women of reproductive age with an active hypothalamic-pituitary-ovarian axis. Pelvic endometriosis typically occurs in women aged 25-30 years. Extrapelvic manifestations of this disorder occur in woman aged 35-40 years. Women younger than 20 years with this disease often have anomalies of the reproductive system. Prepubertal girls do not seem to be at risk for this disease, although the number of reports of endometriosis in young women shortly after menarche is increasing.

Menopause (whether spontaneous or induced through surgical or medical means) usually leads to resolution of symptoms. The disease seems to remain quiescent even in the face of hormone replacement therapy.



Endometriosis has been found to resolve spontaneously in one third of women who are not actively treated.[37] However, it is generally a progressive disease, with an unpredictable extent of progression and subsequent morbidity. Although most patients (up to 95% in some studies) respond to medical therapy (suppression of ovulation) for decreasing pelvic pain, such therapy is ineffective for treatment of endometriosis-associated infertility but does preserve the potential for conception. Nonetheless, as many as 50% of women have a return of symptoms within 5 years with medical management.

Combination estrogens/progestins relieve pain in as many as 80-85% of patients with endometriosis-related pelvic pain. After 6 months of danazol therapy, as many as 90% of patients with moderate endometriosis experience adequate pain relief.

Findings from the prospective Australian Longitudinal Study on Women's Health of 9,585 women (age at trial onset, 18-23 y) indicated that, regardless of fertility status, previous exposure to oral contraceptive pills (OCPs) reduced the risk of a subsequent diagnosis of endometriosis among parous women but increased the risk among nulliparous women.[38]

Relative to women who never used OCPs, the hazard ratio (HR) for endometriosis among women with up to 5 years of OCP use before diagnosis was 1.8 in nulliparous women compared with 0.41 in parous women. In those with a history of OCP use for 5 years or longer, the HR was 2.3 in nulliparous women and 0.45 in parous women.[38] The investigators suggested a possible reason for the twofold increased risk of endometriosis among the nulliparous women may have been early noncontraceptive use of OCPs.

Minimally invasive surgical therapy affords better fertility rates, but this treatment is not as effective at eliminating pain. Definitive surgical therapy (total hysterectomy with bilateral salpingo-oophorectomy [TAH-BSO] and peritoneal stripping) offers the best chance for long-term resolution of pain (up to 90%). However, reserve this option as a last resort in patients with completely incapacitating disability or those who have no desire for future childbearing.

In general, pregnancy is possible but depends on the severity of the disease. Endometriosis signs and symptoms generally regress with the onset of menopause and during pregnancy.


Acute or chronic pelvic pain is common in patients with endometriosis. Infertility is also common. Approximately 30-40% of women with endometriosis will be subfertile.

Adolescent patients typically present with increasingly severe dysmenorrhea and/or chronic pelvic pain. Any persistent symptoms that seem cyclic in nature should prompt the practitioner to consider a search for endometriosis.

Symptoms do not correlate well with disease severity. Significant dysfunction can be present with minimal gross disease, whereas severe endometriosis is sometimes asymptomatic. The pain of endometriosis responds poorly to antiprostaglandins and OCPs. Symptoms are related to the site of endometriotic implants and the organ system involved.

Cases have been reported of extrapelvic involvement in virtually every other organ system including the central nervous system (CNS), lungs, pleura, kidney, and bladder.[24, 25] The gastrointestinal (GI) tract is the most common extrapelvic site of endometriosis, and symptoms include bowel obstruction, rectal bleeding, and constipation. Symptoms in other locations are related to the site and size of endometrial implants.

Mortality is negligible.


Complications of endometriosis may include or fall into the following 3 categories:

  • Infertility/subfertility
  • Chronic pelvic pain and subsequent disability
  • Anatomic disruption of involved organ systems (eg, adhesions, ruptured cysts)

Patient Education

Stress to patients the importance of continuing medical therapy for the full 6-month course. Medical therapy often relieves pain but induces uncomfortable adverse effects, and the patient needs encouragement to complete the course of treatment. Recurrence of symptoms after therapy should prompt the patient to return for further evaluation. Educate patients with severe disease about the symptoms of bowel and ureteral obstruction.

For patient education information, see Pregnancy Center and Women's Health Center, as well as Endometriosis, Female Sexual Problems, Birth Control Overview, and Birth Control Methods.

For patients interested in more information or support groups, Endometriosis Research at the National Institutes of Health (NIH), The Endometriosis Association, and are valuable resources.

Contributor Information and Disclosures

G Willy Davila, MD Chairman, Department of Gynecology, Section of Urogynecology and Reconstructive Pelvic Surgery, Cleveland Clinic Florida

G Willy Davila, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Colorado Medical Society, Florida Medical Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: AMS/Astora; Astellas, Uroplasty/Cogentix<br/>Received research grant from: Pfizer; A-Cell; Coloplast; Cook Myocyte.


Elizabeth Alderman, MD Director, Pediatric Residency Program, Director of Fellowship Training Program, Adolescent Medicine, Professor of Clinical Pediatrics, Department of Pediatrics, Division of Adolescent Medicine, Albert Einstein College of Medicine and Children's Hospital at Montefiore

Elizabeth Alderman, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, North American Society for Pediatric and Adolescent Gynecology, Society for Adolescent Health and Medicine

Disclosure: Nothing to disclose.

Gamal Mostafa Ghoniem, MD, FACS Professor and Vice Chair of Urology, Chief, Division of Female Urology, Pelvic Reconstructive Surgery, and Voiding Dysfunction, Department of Urology, University of California, Irvine, School of Medicine

Gamal Mostafa Ghoniem, MD, FACS is a member of the following medical societies: American Urogynecologic Society, International Continence Society, International Urogynaecology Association, Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction, American College of Surgeons, American Urological Association

Disclosure: Received honoraria from Astellas for speaking and teaching; Received grant/research funds from Uroplasty for none; Partner received honoraria from Allergan for speaking and teaching.

Dharmesh Kapoor, MD, MBBS, MRCOG Consultant Gynecologist, Royal Bournemouth Hospital

Disclosure: Nothing to disclose.

Mark K Y Hiraoka, MD Assistant Professor of Obstetrics and Gynecology, University of Hawaii, John A Burns School of Medicine; Consulting Staff, Department of Obstetrics and Gynecology, Queen's Medical Center

Mark K Y Hiraoka, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Association of Professors of Gynecology and Obstetrics

Disclosure: Nothing to disclose.

Barry D Peskin, MD, MBA Head, Section of Ambulatory Gynecology, Department of Gynecology, Cleveland Clinic, Florida

Barry D Peskin, MD, MBA is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine, Cleveland Society of Obstetricians and Gynecologists, North American Menopause Society, Ohio State Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Frances E Casey, MD, MPH Director of Family Planning Services, Department of Obstetrics and Gynecology, VCU Medical Center

Frances E Casey, MD, MPH is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Reproductive Health Professionals, Society of Family Planning, National Abortion Federation, Physicians for Reproductive Health

Disclosure: Nothing to disclose.

Chief Editor

Michel E Rivlin, MD Former Professor, Department of Obstetrics and Gynecology, University of Mississippi School of Medicine

Michel E Rivlin, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Mississippi State Medical Association, Royal College of Surgeons of Edinburgh, Royal College of Obstetricians and Gynaecologists

Disclosure: Nothing to disclose.

Additional Contributors

Thomas Michael Price, MD Associate Professor, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Director of Reproductive Endocrinology and Infertility Fellowship Program, Duke University Medical Center

Thomas Michael Price, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Obstetricians and Gynecologists, Phi Beta Kappa, Society for Reproductive Investigation, Society for Reproductive Endocrinology and Infertility, American Society for Reproductive Medicine

Disclosure: Received research grant from: Insigtec Inc<br/>Received consulting fee from Clinical Advisors Group for consulting; Received consulting fee from MEDA Corp Consulting for consulting; Received consulting fee from Gerson Lehrman Group Advisor for consulting; Received honoraria from ABOG for board membership.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Tod C Aeby, MD,to the development and writing of a source article.

  1. Buchweitz O, Poel T, Diedrich K, Malik E. The diagnostic dilemma of minimal and mild endometriosis under routine conditions. J Am Assoc Gynecol Laparosc. 2003 Feb. 10(1):85-9. [Medline].

  2. Shepard MK, Mancini MC, Campbell GD Jr, George R. Right-sided hemothorax and recurrent abdominal pain in a 34-year-old woman. Chest. 1993 Apr. 103(4):1239-40. [Medline].

  3. Mounsey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am Fam Physician. 2006 Aug 15. 74(4):594-600. [Medline].

  4. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005 Oct. 20(10):2698-704. [Medline].

  5. Kingsberg SA, Janata JW. Female sexual disorders: assessment, diagnosis, and treatment. Urol Clin North Am. 2007 Nov. 34(4):497-506, v-vi. [Medline].

  6. Namnoum AB, Hickman TN, Goodman SB, Gehlbach DL, Rock JA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril. 1995 Nov. 64(5):898-902. [Medline].

  7. Liu DT, Hitchcock A. Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathology. Br J Obstet Gynaecol. 1986 Aug. 93(8):859-62. [Medline].

  8. Kruitwagen RF, Poels LG, Willemsen WN, de Ronde IJ, Jap PH, Rolland R. Endometrial epithelial cells in peritoneal fluid during the early follicular phase. Fertil Steril. 1991 Feb. 55(2):297-303. [Medline].

  9. Scott RB, Te Linde RW, Wharton LR Jr. Further studies on experimental endometriosis. Am J Obstet Gynecol. 1953;66:1082:

  10. D'Hooghe TM, Bambra CS, Raeymaekers BM, Koninckx PR. Increased prevalence and recurrence of retrograde menstruation in baboons with spontaneous endometriosis. Hum Reprod. 1996 Sep. 11(9):2022-5. [Medline].

  11. Mathur S, Peress MR, Williamson HO, Youmans CD, Maney SA, Garvin AJ, et al. Autoimmunity to endometrium and ovary in endometriosis. Clin Exp Immunol. 1982 Nov. 50(2):259-66. [Medline]. [Full Text].

  12. Acién P, Velasco I, Gutiérrez M, Martínez-Beltrán M. Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings. Fertil Steril. 2007 Jul. 88(1):32-8. [Medline].

  13. Matsuzaki S, Canis M, Pouly JL, Wattiez A, Okamura K, Mage G. Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertil Steril. 2004 Nov. 82(5):1309-15. [Medline].

  14. Wölfler MM, Nagele F, Kolbus A, Seidl S, Schneider B, Huber JC, et al. A predictive model for endometriosis. Hum Reprod. 2005 Jun. 20(6):1702-8. [Medline].

  15. Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril. 1999 Dec. 72(6):961-9. [Medline].

  16. Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril. 2004 May. 81(5):1395-8. [Medline].

  17. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril. 2004 Feb. 81(2):290-6. [Medline].

  18. Suginami H. A reappraisal of the coelomic metaplasia theory by reviewing endometriosis occurring in unusual sites and instances. Am J Obstet Gynecol. 1991 Jul. 165(1):214-8. [Medline].

  19. Metzger DA, Lessey BA, Soper JT, McCarty KS Jr, Haney AF. Hormone-resistant endometriosis following total abdominal hysterectomy and bilateral salpingo-oophorectomy: correlation with histology and steroid receptor content. Obstet Gynecol. 1991 Nov. 78(5 Pt 2):946-50. [Medline].

  20. Schrodt GR, Alcorn MO, Ibanez J. Endometriosis of the male urinary system: a case report. J Urol. 1980 Nov. 124(5):722-3. [Medline].

  21. Ueki M. Histologic study of endometriosis and examination of lymphatic drainage in and from the uterus. Am J Obstet Gynecol. 1991 Jul. 165(1):201-9. [Medline].

  22. Kadan Y, Fiascone S, McCourt C, et al. Predictive factors for the presence of malignant transformation of pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol. 2014 Dec 2. 185C:23-27. [Medline].

  23. Lobo RA. Endometriosis: etiology, pathology, diagnosis, management. Comprehensive Gynecology. Philadelphia, PA: Mosby; 5th ed. 2007:chap 19.

  24. Markham SM, Carpenter SE, Rock JA. Extrapelvic endometriosis. Obstet Gynecol Clin North Am. 1989 Mar. 16(1):193-219. [Medline].

  25. Jubanyik KJ, Comite F. Extrapelvic endometriosis. Obstet Gynecol Clin North Am. 1997 Jun. 24(2):411-40. [Medline].

  26. ACOG practice bulletin. Medical management of endometriosis. Number 11, December 1999 (replaces Technical Bulletin Number 184, September 1993). Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet. 2000 Nov. 71(2):183-96. [Medline].

  27. Wheeler JM. Epidemiology of endometriosis-associated infertility. J Reprod Med. 1989 Jan. 34(1):41-6. [Medline].

  28. Rawson JM. Prevalence of endometriosis in asymptomatic women. J Reprod Med. 1991 Jul. 36(7):513-5. [Medline].

  29. Strathy JH, Molgaard CA, Coulam CB, Melton LJ 3rd. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril. 1982 Dec. 38(6):667-72. [Medline].

  30. Verkauf BS. Incidence, symptoms, and signs of endometriosis in fertile and infertile women. J Fla Med Assoc. 1987 Sep. 74(9):671-5. [Medline].

  31. Carter JE. Combined hysteroscopic and laparoscopic findings in patients with chronic pelvic pain. J Am Assoc Gynecol Laparosc. 1994 Nov. 2(1):43-7. [Medline].

  32. Kontoravdis A, Hassan E, Hassiakos D, Botsis D, Kontoravdis N, Creatsas G. Laparoscopic evaluation and management of chronic pelvic pain during adolescence. Clin Exp Obstet Gynecol. 1999. 26(2):76-7. [Medline].

  33. Williams TJ, Pratt JH. Endometriosis in 1,000 consecutive celiotomies: incidence and management. Am J Obstet Gynecol. 1977 Oct 1. 129(3):245-50. [Medline].

  34. Cramer DW. Epidemiology of endometriosis. Wilson EA, ed. Endometriosis. New York, NY: Alan R. Liss; 1987:5-22.

  35. Hadfield RM, Mardon HJ, Barlow DH, Kennedy SH. Endometriosis in monozygotic twins. Fertil Steril. 1997 Nov. 68(5):941-2. [Medline].

  36. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997 Jun. 24(2):235-58. [Medline].

  37. Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril. 2000 Jul. 74(1):24-30. [Medline].

  38. Tu FF, Du H, Goldstein GP, Beaumont JL, Zhou Y, Brown WJ. The influence of prior oral contraceptive use on risk of endometriosis is conditional on parity. Fertil Steril. 2014 Mar 22. [Medline].

  39. Demco L. Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy. J Am Assoc Gynecol Laparosc. 1998 Aug. 5(3):241-5. [Medline].

  40. Koninckx PR, Martin DC. Deep endometriosis: a consequence of infiltration or retraction or possibly adenomyosis externa?. Fertil Steril. 1992 Nov. 58(5):924-8. [Medline].

  41. Koninckx PR, Oosterlynck D, D'Hooghe T, Meuleman C. Deeply infiltrating endometriosis is a disease whereas mild endometriosis could be considered a non-disease. Ann N Y Acad Sci. 1994 Sep 30. 734:333-41. [Medline].

  42. Ferrero S, Esposito F, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Quality of sex life in women with endometriosis and deep dyspareunia. Fertil Steril. 2005 Mar. 83(3):573-9. [Medline].

  43. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997 May. 67(5):817-21. [Medline].

  44. Hornstein MD, Gleason RE, Orav J, Haas ST, Friedman AJ, Rein MS, et al. The reproducibility of the revised American Fertility Society classification of endometriosis. Fertil Steril. 1993 May. 59(5):1015-21. [Medline].

  45. Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril. 1991 Apr. 55(4):759-65. [Medline].

  46. Barbati A, Cosmi EV, Spaziani R, Ventura R, Montanino G. Serum and peritoneal fluid CA-125 levels in patients with endometriosis. Fertil Steril. 1994 Mar. 61(3):438-42. [Medline].

  47. Chen FP, Soong YK, Lee N, Lo SK. The use of serum CA-125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis. Acta Obstet Gynecol Scand. 1998 Jul. 77(6):665-70. [Medline].

  48. Yeaman GR, Collins JE, Lang GA. Autoantibody responses to carbohydrate epitopes in endometriosis. Ann N Y Acad Sci. 2002 Mar. 955:174-82; discussion 199-200, 396-406. [Medline].

  49. Agic A, Djalali S, Wolfler MM, Halis G, Diedrich K, Hornung D. Combination of CCR1 mRNA, MCP1, and CA125 measurements in peripheral blood as a diagnostic test for endometriosis. Reprod Sci. 2008 Nov. 15(9):906-11. [Medline].

  50. Mukund J. Sonography of adnexal masses. Ultrasound Clinics. January 2007;2(1):133-53:

  51. Kinkel K, Chapron C, Balleyguier C, Fritel X, Dubuisson JB, Moreau JF. Magnetic resonance imaging characteristics of deep endometriosis. Hum Reprod. 1999 Apr. 14(4):1080-6. [Medline].

  52. Takeuchi H, Kuwatsuru R, Kitade M, Sakurai A, Kikuchi I, Shimanuki H, et al. A novel technique using magnetic resonance imaging jelly for evaluation of rectovaginal endometriosis. Fertil Steril. 2005 Feb. 83(2):442-7. [Medline].

  53. Stewart CJ, Leung Y, Walsh MD, Walters RJ, Young JP, Buchanan DD. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol. 2012 Feb 1. [Medline].

  54. Sutton CJ, Pooley AS, Ewen SP, Haines P. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril. 1997 Dec. 68(6):1070-4. [Medline].

  55. Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril. 1993 Mar. 59(3):511-5. [Medline].

  56. Reeve L, Lashen H, Pacey AA. Endometriosis affects sperm-endosalpingeal interactions. Hum Reprod. 2005 Feb. 20(2):448-51. [Medline].

  57. Badawy SZ, ElBakry MM, Samuel F, Dizer M. Cumulative pregnancy rates in infertile women with endometriosis. J Reprod Med. 1988 Sep. 33(9):757-60. [Medline].

  58. Marcoux S, Maheux R, Bérubé S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med. 1997 Jul 24. 337(4):217-22. [Medline].

  59. Bukulmez O, Yarali H, Gurgan T. The presence and extent of endometriosis do not effect clinical pregnancy and implantation rates in patients undergoing intracytoplasmic sperm injection. Eur J Obstet Gynecol Reprod Biol. 2001 May. 96(1):102-7. [Medline].

  60. Hughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev. 2007 Jul 18. CD000155. [Medline].

  61. Benschop L, Farquhar C, van der Poel N, Heineman MJ. Interventions for women with endometrioma prior to assisted reproductive technology. Cochrane Database Syst Rev. 2010 Nov 10. CD008571. [Medline].

  62. Hamdan M, Omar SZ, Dunselman G, Cheong Y. Influence of Endometriosis on Assisted Reproductive Technology Outcomes: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015 Jan. 125(1):79-88. [Medline].

  63. Vercammen EE, D'Hooghe TM. Endometriosis and recurrent pregnancy loss. Semin Reprod Med. 2000. 18(4):363-8. [Medline].

  64. Allen C, Hopewell S, Prentice A, Gregory D. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2009 Apr 15. CD004753. [Medline].

  65. Nawathe A, Patwardhan S, Yates D, Harrison GR, Khan KS. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG. 2008 Jun. 115(7):818-22. [Medline].

  66. Guzick DS, Huang LS, Broadman BA, Nealon M, Hornstein MD. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. 2011 Apr. 95(5):1568-73. [Medline].

  67. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004 Sep. 191(3):733-40. [Medline].

  68. Hull ME, Moghissi KS, Magyar DF, Hayes MF. Comparison of different treatment modalities of endometriosis in infertile women. Fertil Steril. 1987 Jan. 47(1):40-4. [Medline].

  69. Kauppila A. Changing concepts of medical treatment of endometriosis. Acta Obstet Gynecol Scand. 1993 Jul. 72(5):324-36. [Medline].

  70. Schlaff WD, Dugoff L, Damewood MD, Rock JA. Megestrol acetate for treatment of endometriosis. Obstet Gynecol. 1990 Apr. 75(4):646-8. [Medline].

  71. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol. 2006 Mar 1. 125(1):9-28. [Medline].

  72. Anpalagan A, Condous G. Is there a role for use of levonorgestrel intrauterine system in women with chronic pelvic pain?. J Minim Invasive Gynecol. 2008 Nov-Dec. 15(6):663-6. [Medline].

  73. Hughes E, Fedorkow D, Collins J, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev. 2000. CD000155. [Medline].

  74. Winkel CA, Scialli AR. Medical and surgical therapies for pain associated with endometriosis. J Womens Health Gend Based Med. 2001 Mar. 10(2):137-62. [Medline].

  75. Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E, et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril. 1996 Apr. 65(4):707-10. [Medline].

  76. Friedman AJ, Hornstein MD. Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain. Fertil Steril. 1993 Aug. 60(2):236-41. [Medline].

  77. Taskin O, Yalcinoglu AI, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril. 1997 Jan. 67(1):40-5. [Medline].

  78. Surrey ES, Voigt B, Fournet N, Judd HL. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy. Fertil Steril. 1995 Apr. 63(4):747-55. [Medline].

  79. Lane N, Baptista J, Snow-Harter C. Bone mineral density of the lumbar spine in endometriosis subjects compared to an age-similar control population. J Clin Endocrinol Metab. 1991 Feb. 72(2):510-4. [Medline].

  80. Surrey E, Hornstein M. Prolonged GnRH agonist add back therapy for symptomatic endometriosis patients: Long-term follow-up of a 12-month clinical trial. Fertil Steril. 1999;72:S80.

  81. Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol. 1999 Jan. 93(1):51-8. [Medline].

  82. Espaulella J, Armengol J, Bella F, Lain JM, Calaf J. Pulmonary endometriosis: conservative treatment with GnRH agonists. Obstet Gynecol. 1991 Sep. 78(3 Pt 2):535-7. [Medline].

  83. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2010 Dec 8. CD008475. [Medline].

  84. Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol. 1987 Mar. 1(1):13-23. [Medline].

  85. Dmowski WP, Kapetanakis E, Scommegna A. Variable effects of danazol on endometriosis at 4 low-dose levels. Obstet Gynecol. 1982 Apr. 59(4):408-15. [Medline].

  86. Razzi S, Luisi S, Calonaci F, Altomare A, Bocchi C, Petraglia F. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril. 2007 Oct. 88(4):789-94. [Medline].

  87. Al Kadri H, Hassan S, Al-Fozan HM, Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst Rev. 2009 Jan 21. CD005997. [Medline].

  88. Cook AS, Rock JA. The role of laparoscopy in the treatment of endometriosis. Fertil Steril. 1991 Apr. 55(4):663-80. [Medline].

  89. Saidi MH, Vancaillie TG, White AJ, Sadler RK, Akright BD, Farhart SA. Complications of major operative laparoscopy. A review of 452 cases. J Reprod Med. 1996 Jul. 41(7):471-6. [Medline].

  90. Revelli A, Modotti M, Ansaldi C, Massobrio M. Recurrent endometriosis: a review of biological and clinical aspects. Obstet Gynecol Surv. 1995 Oct. 50(10):747-54. [Medline].

  91. Jones KD, Sutton C. Patient satisfaction and changes in pain scores after ablative laparoscopic surgery for stage III-IV endometriosis and endometriotic cysts. Fertil Steril. 2003 May. 79(5):1086-90. [Medline].

  92. Beretta P, Franchi M, Ghezzi F, Busacca M, Zupi E, Bolis P. Randomized clinical trial of two laparoscopic treatments of endometriomas: cystectomy versus drainage and coagulation. Fertil Steril. 1998 Dec. 70(6):1176-80. [Medline].

  93. Alborzi S, Momtahan M, Parsanezhad ME, Dehbashi S, Zolghadri J, Alborzi S. A prospective, randomized study comparing laparoscopic ovarian cystectomy versus fenestration and coagulation in patients with endometriomas. Fertil Steril. 2004 Dec. 82(6):1633-7. [Medline].

  94. Donnez J, Nisolle M, Clerckx F. Evaluation of preoperative use of danazol, gestrinone, lynestrol, buserelin spray and buserelin implant, in the treatment of endometriosis related infertility. Chadha DR, Buttram VC Jr, eds. Current Concepts in Endometriosis. New York, NY: Alan R. Liss; 1990:427-42;

  95. Vercellini P, Crosignani PG, Abbiati A, Somigliana E, Viganò P, Fedele L. The effect of surgery for symptomatic endometriosis: the other side of the story. Hum Reprod Update. 2009 Mar-Apr. 15(2):177-88. [Medline].

  96. Johnson NP. A review of the use of lipiodol flushing for unexplained infertility. Treat Endocrinol. 2005. 4(4):233-43. [Medline].

  97. Wilson ML, Farquhar CM, Sinclair OJ, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2000. CD001896. [Medline].

  98. Proctor ML, Latthe PM, Farquhar CM, Khan KS, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2005 Oct 19. CD001896. [Medline].

  99. Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev. 2000. CD002122. [Medline].

  100. Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2000. CD000346. [Medline].

  101. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2001. CD000068. [Medline].

  102. Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2000. CD001019. [Medline].

  103. Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril. 1997 Sep. 68(3):393-401. [Medline].

  104. Society of Obstetricians and Gynaecologists of Canada. Canadian consensus conference on endometriosis consensus statements. J SOGC. 1999;21:471-3.

  105. Redwine DB. Endometriosis persisting after castration: clinical characteristics and results of surgical management. Obstet Gynecol. 1994 Mar. 83(3):405-13. [Medline].

  106. Hickman TN, Namnoum AB, Hinton EL, Zacur HA, Rock JA. Timing of estrogen replacement therapy following hysterectomy with oophorectomy for endometriosis. Obstet Gynecol. 1998 May. 91(5 Pt 1):673-7. [Medline].

  107. Mu F, Rich-Edwards J, Rimm EB, Spiegelman D, Missmer SA. Endometriosis and Risk of Coronary Heart Disease. Circ Cardiovasc Qual Outcomes. 2016 Mar 29. [Medline].

  108. Wendling P. Study Puts Endometriosis in Cardiologists' Sights. Heartwire from Medscape. Available at March 31, 2016; Accessed: April 25, 2016.

  109. Johnson KM. Endometriosis. The case for early, aggressive treatment. J Reprod Med. 1998 Mar. 43(3 Suppl):309-15. [Medline].

  110. American College of Obstetricians and Gynecologists. Endometriosis in Adolescents. Committee Opinion. April 2005;Number 310:1-7.

  111. Busacca M, Chiaffarino F, Candiani M, Vignali M, Bertulessi C, Oggioni G, et al. Determinants of long-term clinically detected recurrence rates of deep, ovarian, and pelvic endometriosis. Am J Obstet Gynecol. 2006 Aug. 195(2):426-32. [Medline].

  112. Doyle JO, Missmer SA, Laufer MR. The effect of combined surgical-medical intervention on the progression of endometriosis in an adolescent and young adult population. J Pediatr Adolesc Gynecol. 2009 Aug. 22(4):257-63. [Medline].

  113. Drosdzol A, Skrzypulec V. [Dysmenorrhea in pediatric and adolescent gynaecology]. Ginekol Pol. 2008 Jul. 79(7):499-503. [Medline].

  114. Ferrero S, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Future perspectives in the medical treatment of endometriosis. Obstet Gynecol Surv. 2005 Dec. 60(12):817-26. [Medline].

  115. Good Outcomes With Radical Surgery for Moderate-Severe Endometriosis. Medscape. Apr 30 2013. Available at Accessed: May 1 2013.

  116. Hummelshoj L, Prentice A, Groothuis P. Update on endometriosis. Women's Health. 2006;2(1):53-56.

  117. Meuleman C, Tomassetti C, Wolthuis A, Van Cleynenbreugel B, Laenen A, Penninckx F, et al. Clinical Outcome After Radical Excision of Moderate-Severe Endometriosis With or Without Bowel Resection and Reanastomosis: A Prospective Cohort Study. Ann Surg. 2013 Apr 10. [Medline].

  118. Wayne PM, Kerr CE, Schnyer RN, Legedza AT, Savetsky-German J, Shields MH, et al. Japanese-style acupuncture for endometriosis-related pelvic pain in adolescents and young women: results of a randomized sham-controlled trial. J Pediatr Adolesc Gynecol. 2008 Oct. 21(5):247-57. [Medline]. [Full Text].

Powder-burn lesions of endometriosis.
Endometriosis. Chocolate cyst of the ovary.
Endometriosis. Red lesions on the sigmoid colon and cul-de-sac.
Adhesions due to endometriosis.
Endometriosis. Red lesions on various organs.
Active endometriosis with red and powder-burn lesions and adhesions from old scarring.
Scarring due to old disease and active endometriosis.
Endometriosis. Moderate-to-severe disease.
Typical appearance of minimal endometriosis on the uterosacral ligaments. Note that some are pigmented (contain hemosiderin), whereas others are not.
Peritoneal erosions and adhesions in the posterior cul-de-sac. These are typical of more severe endometriosis.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.